News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA) to Start China Clinical Trial of Cancer Drug In-licensed from Shanghai Institutes for Biological Sciences



5/29/2012 9:19:32 AM

by Richard Daverman, PhD

May 25, 2012 -- Sanofi hopes to begin a Phase I clinical trial in China next year of a novel drug that targets liver cancer. The molecule inhibits the slit-robo signaling path that controls tumor vasculature and tumor growth, a discovery made by researchers at the Shanghai Institute of Biological Sciences (SIBS). Sanofi in-licensed global rights from SIBS to the molecule in 2010 for a reported $60 million upfront payment. More details....

Stock Symbol: (NYSE: SNY)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES